Harnessing the anti-inflammatory effects of topical dapsone for management of acne

Journal of Drugs in Dermatology

Volumn 9, Issue 6, 2010, Pages 667-671

  Kircik, Leon H ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; COTRIMOXAZOLE; DAPSONE; DIETHYLENE GLYCOL MONOETHYL ETHER; PROSTAGLANDIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; DRUG VEHICLE;

ACNE; ACNE VULGARIS; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; CLINICAL PROTOCOL; DERMATITIS HERPETIFORMIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; LEPROSY; LONG TERM CARE; METHEMOGLOBINEMIA; PEMPHIGUS VULGARIS; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; REVIEW; TOPICAL DRUG ADMINISTRATION; VEHICLES;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; DAPSONE; DRUG THERAPY, COMBINATION; HUMANS; VEHICLES;

EID: 77955893553     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Grange PA, Chéreau C, Raingeaud J, et al. Production of superoxide anions by keratinocytes initiates P. acnes-induced inflammation of the skin. PLoS Pathog. 2009;5(7):e1000527.
2. Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-B and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691-1699. (Pubitemid 40734392)
3. Schmidt E, Reimer S, Kruse N, et al. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol. 2001;124:157-162. (Pubitemid 32476946)
4. Sally A, Booth SA, Moody CE, et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol. 1992;98:135-140.
5. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: Inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transaction. J Leukoc Biol. 1997;62:827-836. (Pubitemid 28015631)
6. Suda T, Suzuki Y, Matsui T. Dapsone suppresses human neutrophil superoxide production and elastase release in calcium-dependent manner. Br J Dermatol. 2005;152:887-895. (Pubitemid 40704926)
7. Bonney RJ, Wightman PD, Dahlgren ME, et al. Inhibition of prostaglandins, leukotrienes, and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. Biocheml Pharm. 1983;32(2):361-366. (Pubitemid 13184477)
8. Abe M, Shimizu A, Yokoyama Y, et al. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-a production from activated mononuclear cells on cutaneous lupus erythematosus. Clin Exper Dermatol. 2008;33:759-763.
9. Wozel G, Lehmann B. Dapsone inhibits the generation of 5-lipoxy-genase products in human polymorphonuclear leukocytes. Skin Pharmacol. 1995;8:196-202.
10. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: Overview and update. J Am Acad Dermatol. 2001;45(3):420-434. (Pubitemid 32800500)
11. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. New Eng J Med. 2003;349(17):1628-1635 (Pubitemid 37288569)
12. Lewis AJ, Gemmell DK, Stimson WH. The anti-inflammatory profile of dapsone in animal models of inflammation. Agents Actions. 1978;8(6):578-586. (Pubitemid 9079243)
13. Williams K, Capstick RB, Lewis DA, Best R. Anti-inflammatory actions of dapsone and its related biochemistry. J Pharm Pharmacol. 1976;28(7):555-558.
14. Ottonello L, Dapino P, Scorpcco MC, et al. Sulphonamides as antiinflammatory agents: Old drugs for new therapeutic strategies in neutrophilic inflammation? Clin Sci (Lond). 1995;88(3):331-336.
15. Diaz-Ruiz A, Zavala C, Montes S, et al. Antioxidant, antiinflammatory and antiapoptotic effects of dapsone in a model of brain ischemia/reperfusion in rats. J Neurosci Res. 2008.
16. Tingle MD, Mahmud R, Maggs JL, et al. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. Pharmcology. 1997;283(2):817-823. (Pubitemid 27514644)
17. Thiboutot DM, Willmer J, Sharata H, et al. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet. 2007;46(8):697-712. (Pubitemid 47204855)
18. Del Rosso JQ. Newer topical therapies for the treatment of acne vulgaris. Cutis. 2007;80(5):400-410.
19. Draelos ZD, Carter E, Maloney JM, et al.; United States/Canada Dapsone Gel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439.e1-10.
20. Lucky AW, Maloney JM, Roberts J, et al.; Dapsone Gel Long-Term Safety Study Group. Dapsone gel 5% for the treatment of acne vulgaris: Safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol. 2007;6(10):981-987.
21. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm. 1999;184(1):1-6. (Pubitemid 29308990)
22. Bonina FP, Montenegro L. Effects of some non-toxic penetration enhancers on in vitro heparin skin permeation from gel vehicles. Int J Pharm. 1994;111:191-196. (Pubitemid 24288895)
23. Godwin DA, Kim N, Felton LA. Influence of transcutol CG on the skin accumulation and transdermal permeation of ultraviolet absorbers. Eur J Pharm Biopharm. 2002;53:23-27. (Pubitemid 34036994)
24. Otto A, Wiechers JW, Kelly CL, et al. Effect of penetration modifiers on the dermal and transdermal delivery of drugs and cosmetic active ingredients. Skin Pharmacol Physiol. 2008;21:326-334.